R Bruce Montgomery
Overview
Explore the profile of R Bruce Montgomery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2651
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raychaudhuri R, Lin D, Montgomery R
JAMA
. 2025 Mar;
PMID: 40063046
Importance: Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299 010 new cases and 35 250 deaths in 2024. Prostate cancer is...
2.
Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102208.
PMID: 39265260
Background: Small cell bladder cancer (SCBC) is a rare histologic subtype with relative paucity of data regarding treatment response and outcomes. We reviewed 2 databases to compare outcomes in patients...
3.
Frank S, Persse T, Coleman I, Bankhead 3rd A, Li D, De-Sarkar N, et al.
bioRxiv
. 2024 Jul;
PMID: 39071291
Genomic loss of the transcriptional kinase occurs in ~6% of metastatic castration-resistant prostate cancers (mCRPC) and correlates with poor patient outcomes. Prior studies demonstrate that acute CDK12 loss confers a...
4.
Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, et al.
Clin Genitourin Cancer
. 2024 May;
22(3):102100.
PMID: 38763862
Objectives: Patients with histologic subtype bladder cancer (HSBC) suffer worse outcomes than those with conventional urothelial carcinoma (UC). We sought to characterize the use of adjuvant chemotherapy (AC) in HSBC...
5.
Schoen M, Montgomery R, Owens L, Khan S, Sanfilippo K, Etzioni R
JAMA Netw Open
. 2024 Mar;
7(3):e241970.
PMID: 38470422
No abstract available.
6.
Sekar R, Diamantopoulos L, Bakaloudi D, Khaki A, Grivas P, Winters B, et al.
Clin Genitourin Cancer
. 2023 May;
21(4):507.e1-507.e14.
PMID: 37150667
Introduction: To examine oncologic outcomes and response to neoadjuvant chemotherapy (NAC) in patients with sarcomatoid urothelial carcinoma (SUC) treated with radical cystectomy (RC). Materials And Methods: We retrospectively queried our...
7.
Ghali F, Zhao Y, Patel D, Jewell T, Yu E, Grivas P, et al.
Eur Urol Open Sci
. 2023 Jan;
47:58-64.
PMID: 36601043
Background: Surrogate endpoints (SEs), such as progression-free survival (PFS) and objective response rate (ORR), are frequently used in clinical trials. The relationship between SEs and overall survival (OS) has not...
8.
De Sarkar N, Patton R, Doebley A, Hanratty B, Adil M, Kreitzman A, et al.
Cancer Discov
. 2022 Nov;
13(3):632-653.
PMID: 36399432
Significance: This study provides insights into the dynamics of nucleosome positioning and gene regulation associated with cancer phenotypes that can be ascertained from ctDNA. New methods for classification in phenotype...
9.
Mostaghel E, Marck B, Kolokythas O, Chew F, Yu E, Schweizer M, et al.
Clin Cancer Res
. 2021 Aug;
27(21):6001-6011.
PMID: 34407973
Purpose: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens prior to starting abiraterone acetate (AA) is associated with more rapid progression. We evaluated the effect of AA on androgens...
10.
Nickols N, Goetz M, Graber C, Bhattacharya D, Soo Hoo G, Might M, et al.
Trials
. 2021 Jul;
22(1):431.
PMID: 34225789
Background: Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2 entry into lung epithelium requires the TMPRSS2 cell surface protease. Pre-clinical...